Full-Time
Senior Transformation Manager
Transformation
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$124.5k - $236.5k/yr
Waukegan, IL, USA
Hybrid
Hybrid role; occasional on-site days in North Chicago, IL.
Bachelor's, Master's, MBA
 Business & Strategy (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- 10+ years of experience in transformation delivery, large-scale systems implementation, business process redesign, operations, or management consulting
- Demonstrated track record of leading complex, cross-functional implementations through the full lifecycle with measurable operational impact
- Strong process design and systems thinking skills, including hands-on experience developing SOPs, playbooks, and transition plans
- Proven ability to influence, align, and drive delivery across senior cross-functional stakeholders spanning business, operations, and technology
- Must have demonstrated organizational and planning skills, excellent verbal and written communication skills
- Must have demonstrated strong project management skills with successful delivery of projects
- Must be able to effectively facilitate the resolution of complex technical, analytical and business issues across functional lines
- Bachelor’s degree in business administration, information technology, engineering, operations management, or a related field
- Master’s degree, MBA or equivalent preferred
- Translates strategic direction into clear workplans, deliverables, and next steps for priority transformation initiatives
- Lead progress of assigned workstreams, helping move initiatives from planning through implementation
- Drive structured problem solving and develop practical recommendations to address issues and support execution
- Conduct research and analysis to inform decisions, clarify requirements, and support advancement of transformation priorities
- Develop materials and tools that help teams execute against agreed plans and sustain progress across initiatives
- Identify execution risks or gaps early and elevate them for resolution
- Operationalize operating model decisions (e.g., roles and responsibilities, decision rights, service levels, offshoring transitions) into concrete process, system, and organizational changes across OneHUB and its functional partners
- Develop standard transformation artifacts (SOPs, transition plans, and playbooks) that can be reused across workstreams, functions, and geographies
- Partner closely with Change Management & Communications, Innovation Excellence, PMO, Operations, and functional leads to ensure systems and process changes are well sequenced, well understood, and well adopted
- Coordinate with external hub operators, system vendors, and implementation partners on delivery timelines, technical dependencies, and quality of execution
- Work hand-in-hand with Change Management & Communications to ensure frontline readiness, stakeholder alignment, and smooth adoption of process and system changes
- Provide regular, structured reporting on systems and process workstream status, delivery milestones, risks, and business impact to the Transformation Office and OneHUB leadership
- Inform the refresh of the OneHUB transformation roadmap by surfacing execution learnings, operating model gaps, and sequencing opportunities across systems, processes, and organizational design
- Master’s degree, MBA or equivalent preferred
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10.2% to $16.99 billion; immunology grew 15.1%.
- FDA and EC approvals expanded Skyrizi and Rinvoq into pediatric psoriasis, vitiligo, alopecia.
- Tavapadon’s FDA review and Apogee closing in Q3 2026 extend pipeline depth.
What critics are saying
- Humira fell 35.9% in Q2 2026; biosimilar erosion keeps crushing legacy cash flows.
- Skyrizi supplies nearly one-third of 2026 revenue; any setback hits valuation immediately.
- AbbVie adds $10.9 billion of debt for Apogee while EPS guidance already fell.
What makes AbbVie unique
- Skyrizi, Rinvoq, and Vraylar drive AbbVie’s post-Humira growth engine.
- AbbVie holds long patent runways: Skyrizi to 2033, Rinvoq to 2037.
- Apogee adds long-acting immunology assets, deepening AbbVie’s inflammatory-disease moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics in June 2026, aiming to strengthen its drug pipeline. The biopharmaceutical company reported FY 2025 revenue of nearly $61.2 billion, up roughly 8.6% year-on-year. Net income reached close to $4.2 billion, reflecting a net margin of approximately 6.9%, down from 7.6% the previous year. Free cash flow for the period was nearly $17.8 billion. CVS Health reported FY 2025 revenue of approximately $402.1 billion, representing growth of nearly 7.8%. The integrated healthcare provider serves around 37 million medical members and manages 1.9 billion prescriptions annually through its Health Services segment. Net income was close to $1.8 billion, yielding a net margin of roughly 0.4%, down from 1.2% in FY 2024.
AbbVie has announced a $9.5 billion senior notes offering across multiple tranches with maturities ranging from 2028 to 2066. The offering includes both floating and fixed rate notes, with the largest tranche being $1.5 billion in 6.00% senior notes due 2066. Morgan Stanley, BofA Securities, J.P. Morgan Securities, and SG Americas Securities are serving as joint book-running managers for the transaction. The proceeds will be used for refinancing existing debt, funding acquisitions, and general corporate purposes. The transaction is being conducted under an effective shelf registration statement and the notes are expected to be listed on the New York Stock Exchange. AbbVie confirmed there have been no material adverse changes in its financial position since year-end 2025.
AbbVie reported second-quarter revenue of $16.99 billion, up 10.2% year-on-year and exceeding analyst expectations of $16.79 billion. Adjusted earnings per share of $3.65 also beat consensus estimates of $3.61. The pharmaceutical company's growth was driven by its immunology portfolio, particularly SKYRIZI and RINVOQ, and neuroscience products including Vraylar and Vialev. CEO Robert Michael noted each portfolio "delivered growth above 20%". However, AbbVie lowered its full-year adjusted earnings guidance to $13.97 per share at the midpoint, a 1.5% decrease. Management attributed the revision to anticipated dilution from the planned Apogee Therapeutics acquisition and increased research and development spending. The company faces ongoing biosimilar pressure on legacy products whilst pursuing regulatory approvals for new indications and preparing to launch Tevapadon for Parkinson's disease.
CARE Philippines launches B-STRONG program in Rizal, aims to combat rising cases of hypertension and diabetes. Rizal Province, Philippines (August 4, 2026) - CARE Philippines officially launched the B-STRONG program in the Province of Rizal on July 23. B-STRONG is a partnership between CARE and the AbbVie Foundation that trains and equips Barangay Health Workers in Rizal Province to connect communities to critical healthcare services and improve health outcomes, by delivering care through existing government health systems. In strong partnership with the Department of Health - Center for Health Development Region IV-A (DOH-CHD IV-A), PhilHealth NCR/Rizal, the Rizal Provincial Government, and all its 14 local government units, the program equips more than 3,000 Barangay Health Workers to connect at-risk households to PhilPEN screening, PhilHealth-YAKAP enrollment, and continuous care for non-communicable diseases (NCDs). Representatives from CARE Philippines, DOH Center for Health Development CaLaBaRZon, PhilHealth NCR, the Provincial Government of Rizal, and 14 LGUs from the province gather for the launch of the B-STRONG Project. "In Rizal alone, thousands of people are living with high blood pressure and diabetes, and most have never been screened," said Reiza Dejito, CARE Philippines' Country Director. Despite this reality, she expressed optimism: "Here's what's giving me hope - the care already exists. YAKAP already covers the medicines. The health centers in the LGUs already do the screening. The piece that we can strengthen together is the connection between them. And this is the whole point of B-STRONG, the connection, the bridge, so when a Barangay Health Worker finds a family in need, they help connect them to the care that is already there." Photo: DOH Center for Health Development IV-A and CARE Philippines sign a Memorandum of Understanding. Representing the organizations are (L-R): Glenn Bede Benablo, B-STRONG Project Manager; Dr. Marie Beatrix Duzon, NCD Cluster Head, DOH CHD IV-A; Reiza Dejito, CARE Philippines Country Director; and Jerome Lanit, CARE Philippines Development Portfolio Coordinator. CARE Philippines also formalized their partnership with DOH-CHD IV-A, PhilHealth Regional Office NCR, and the Provincial Government of Rizal through a Memorandum of Understanding (MOU) signing. Vice President of PhilHealth NCR, Dr. Bernadette Lico remarked: "Through the B-STRONG program and its synergy with PhilHealth YAKAP, we are strengthening a more coordinated and sustainable approach - one that emphasizes prevention, health promotion and accessible care at the community level." She added, "as we launch this program today, we reaffirm our collective commitment to stronger health systems and more empowered communities, where every Filipino has the opportunity to live a healthier and more productive life." "This is our north star: to reduce premature mortality due to cardiovascular diseases and diabetes mellitus by 20% by 2028. B-STRONG will reach 10,000 high-risk patients - ensuring that NCDs are diagnosed early, referred timely, and controlled effectively," CARE Philippines B-STRONG Project Manager Glenn Bede Benablo emphasized. The event was attended by over 100 health workers, government partners, and development partners at the municipal, provincial, and regional levels. By embedding the model directly into local health infrastructure, B-STRONG helps ensure access to critical services remains sustainable after the program concludes. The program is designed to last beyond the project period and potentially expand to other locations. "The AbbVie Foundation is committed to driving transformative change in communities, and we are proud to partner with CARE to advance this innovative program that is designed to strengthen local health systems and connect people to the care they need," said Keya Milla, President, AbbVie Foundation; Vice President, Corporate Responsibility & Global Philanthropy, AbbVie. "We look forward to seeing B-STRONG's impact on health outcomes in the Philippines | and its potential to serve as a blueprint for communities around the world." About CARE Founded in 1945 with the creation of the CARE Package(R), CARE is a leading humanitarian organization fighting global poverty. CARE places special focus on working alongside women and girls. Equipped with the proper resources, women and girls have the power to lift whole families and entire communities out of poverty. In 2024, CARE worked in 121 countries, reaching 53 million people through 1,450 projects. In the Philippines, CARE has been supporting the most vulnerable communities during times of crisis while also fostering community resilience and development since 1949. To learn more, visit www.care.org and www.care-philippines.org. About the AbbVie Foundation The AbbVie Foundation is a 501(c)(3) nonprofit committed to driving transformative change in communities worldwide and advancing health equity so that every individual can realize their full potential. Media Contacts: Windel Joshua L. Pasion Project Partnerships Officer 0908 318 9560 | [email protected] Mary Therese L. Norbe Communication Specialist, CARE Philippines 0919 911 7534 | [email protected]
AbbVie expects SKYRIZI to generate $21.7 billion of its projected $67.6 billion in 2026 revenue, representing nearly one-third of total sales from a single medicine. The immunology drug sold $5.5 billion in Q2 2026, up 24% operationally, whilst the company's next largest product, RINVOQ, brought in $2.5 billion. The concentration becomes significant as other segments struggle. Oncology revenue fell 2.4% operationally to $1.6 billion, whilst aesthetics slipped 0.9% to $1.3 billion. Neuroscience grew roughly 20% to $3.2 billion. AbbVie's experience with HUMIRA illustrates the biosimilar risk. The former blockbuster fell 36% operationally to $756 million in Q2 2026 due to competition. However, SKYRIZI's US composition-of-matter patent doesn't expire until 2033, with additional patents extending into the mid-2030s. Shares trade at $250.94, up 37% over twelve months, valuing the company at $444 billion.